Cargando…

Age-related changes in mineralocorticoid receptors in rat hearts

Age-related alterations in the renin-angiotensin-aldosterone system (RAAS) have been reported in the cardiovascular system; however, the detailed mechanism of the RAAS component mineralocorticoid receptors (MR) has not been elucidated. The present study aimed to investigate the associations between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Danli, Dong, Ruolan, Zhang, Yanjun, Yang, Yan, Chen, Zhihui, Tang, Ying, Fu, Menglu, Xu, Xizhen, Tu, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411371/ https://www.ncbi.nlm.nih.gov/pubmed/32582979 http://dx.doi.org/10.3892/mmr.2020.11260

Ejemplares similares

Endothelium‐specific CYP2J2 overexpression attenuates age‐related insulin resistance
por: Yang, Yan, et al.
Publicado: (2018)

EETs reduces LPS-induced hyperpermeability by targeting GRP78 mediated Src activation and subsequent Rho/ROCK signaling pathway
por: Dong, Ruolan, et al.
Publicado: (2017)

sEH Inhibitor Tppu Ameliorates Cecal Ligation and Puncture-Induced Sepsis by Regulating Macrophage Functions
por: Chen, Zhihui, et al.
Publicado: (2020)

The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis
por: Luo, Liman, et al.
Publicado: (2020)

Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney
por: Luo, Jinlan, et al.
Publicado: (2021)

Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging
por: Gorini, Stefania, et al.
Publicado: (2019)

Posttranslational Modifications of the Mineralocorticoid Receptor and Cardiovascular Aging
por: Gadasheva, Yekatarina, et al.
Publicado: (2021)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
por: Henrysson, Josefin, et al.
Publicado: (2022)

The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
por: Luo, Liman, et al.
Publicado: (2019)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
por: Duran, Jason M., et al.
Publicado: (2020)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers
por: Tezuka, Yuta, et al.
Publicado: (2022)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
por: MUKANGWA, Memory, et al.
Publicado: (2019)

Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats
por: Yamamoto, Kanako, et al.
Publicado: (2018)

Blocking the Mineralocorticoid Receptor Improves Cognitive Impairment after Anesthesia/Splenectomy in Rats
por: Feng, Xixia, et al.
Publicado: (2021)

Mineralocorticoid receptor blockade for renoprotection
por: Cha, Dae Ryong
Publicado: (2018)

Beneficial Effects of Proanthocyanidins in the Cardiac Alterations Induced by Aldosterone in Rat Heart through Mineralocorticoid Receptor Blockade
por: Martín-Fernández, Beatriz, et al.
Publicado: (2014)

Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity—When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood
por: Griesler, Bruno, et al.
Publicado: (2022)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
por: Berbenetz, Nicolas M., et al.
Publicado: (2016)

Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives
por: Vizzardi, Enrico, et al.
Publicado: (2014)

Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade
por: Jadhav, Uday, et al.
Publicado: (2023)

Expression of amygdala mineralocorticoid receptor and glucocorticoid receptor in the single-prolonged stress rats
por: Han, Fang, et al.
Publicado: (2014)

Principal function of mineralocorticoid signaling suggested by constitutive knockout of the mineralocorticoid receptor in medaka fish
por: Sakamoto, Tatsuya, et al.
Publicado: (2016)

Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism
por: Lin, Yu-Fang, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonists for heart failure: a real‐life observational study
por: Bruno, Noemi, et al.
Publicado: (2018)

Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population
por: Jonsson, Anna, et al.
Publicado: (2018)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
por: Abe, Takuro, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
por: Jonsson Holmdahl, Anna, et al.
Publicado: (2021)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Localization of Mineralocorticoid Receptors at Mammalian Synapses
por: Prager, Eric M., et al.
Publicado: (2010)

Aldosterone and Mineralocorticoid Receptors—Physiology and Pathophysiology
por: Funder, John W.
Publicado: (2017)

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
por: Bamberg, Krister, et al.
Publicado: (2019)

GLUCOCORTICOIDS ACTIVATE CARDIAC MINERALOCORTICOID RECEPTORS IN ADRENALECTOMIZED DAHL SALT-SENSITIVE RATS
por: OHTAKE, MASAFUMI, et al.
Publicado: (2014)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
por: Suzuki, Sho, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
por: Pieronne‐Deperrois, Marie, et al.
Publicado: (2021)

Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction
por: Kagami, Kazuki, et al.
Publicado: (2023)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_638t3lc07fvuki82u23i6bq64j